This interview was recorded on November 16, 2019, at the American Heart Association Scientific Sessions and is a collaboration between MDedge and Medscape. It is published on both websites.
This transcript has been edited for clarity.
Bruce Jancin: I'm Bruce Jancin with MDedge Cardiology News, and I'm speaking with Dr John Spertus of the Mid America Heart Institute about the practice-changing and really remarkable ISCHEMIA study. Almost 5200 patients were randomized. Tell us the high points.
John A. Spertus, MD: First of all, ISCHEMIA questioned and challenged current practice in many parts of the United States and throughout the world. We have an a priori belief that offering revascularization may confer some benefit in terms of preventing a heart attack or death, particularly in patients with high-risk disease. The cornerstone of stratifying risk and identifying those high-risk patients, where we think the benefits would be greater, has traditionally been stress imaging studies or other types of stress tests, depending on where around the world these tests are conducted. We took the patients with the highest risk, excluding those with left main disease, and randomized them to the cath lab to get whatever they needed. When they went to the cath lab, they defined anatomy and a team would decide whether this patient would be better treated with angioplasty, bypass surgery, or medical therapy alone.
Jancin: These were all patients with stable ischemic heart disease.
Spertus: That's very important. And that really mirrors practice today in that once the coronary anatomy is defined on an angiogram, we go straight to revascularization. Randomizing beforehand gives us the opportunity to implement this before we put a patient on a table and do an angiogram. If we found that revascularization was beneficial, we would continue to do what we're doing, but if we found that a conservative strategy of aggressive medical therapy was as good, it would be very awkward to take the patient off the table. So this pre-cath randomization was very important in allowing the results to be applied going forward.
ISCHEMIA was designed to look at major clinical events very carefully: adjudicated heart attacks, strokes, heart failure, sudden cardiac death, unstable angina, and mortality. The second key outcome was quality of life. When we looked at the main outcome of death, myocardial infarction, heart failure, unstable angina, and sudden cardiac death over the course of 4 years of observation, there was no difference between the groups. I say that with a small asterisk because there were absolutely overlapping curves for death. Myocardial infarctions, which were the largest driver of the endpoint, tended to occur more often in the invasive group for the first 2 years and more often in the conservative group in the second 2 years. So the curves crossed. That creates some statistical challenges, but the net net is that at 4 years, there were very comparable rates between the groups, and there was a large resonating belief in the room that we have to follow over a longer period of time to see whether the curves further diverge and there is a substantial difference at 5, 6, 7, 8, 10 years.
The take-home message for me as a practicing cardiologist is that I don't have to feel... that I am doing any harm by trying medicines first.
That being said, a lot of our treatment of patients is trying to help them over the next several years. The study found, importantly, that there was a very significant benefit in terms of angina control, physical function, and quality of life with an invasive strategy. That benefit was seen not only early after randomization at 3 months, but also at 1 and 3 years, and that sustained benefit has not really been seen before. A very important caveat is that patients who had no angina within a month of being randomized got no benefit. The people who clearly benefited in the short run from this invasive approach were the patients who had angina to begin with.
The take-home message for me as a practicing cardiologist is that I don't have to feel that I am doing any harm by trying medicines first to see if it can control their symptomseven in the highest-risk patients with myocardial ischemia. If it does control their symptoms, then I view that as victory. If their symptoms persist or bother them, I can go to angiography and revascularization, knowing that I have not altered their risk of dying or having a heart attack in the short run. I tried medicines, so if they have a complication of the procedure, at least we tried everything else first.
It really opens up a new era of shared decision-making, and ISCHEMIA is providing very comforting evidence that we have time to work with our patients to try alternative approaches to control their symptoms and optimize their quality of life. And with that, I think we can all have confidence that now we can build the tools to help implement these findings and try to tailor the treatment to the risks, goals, and values of our patients.
Jancin: This will be a practice-changing study for sure. Do you think there will be waves of interventional cardiologists who decide that they need to get a new gig and learn how to do revascularization of peripheral arterial disease, for example?
Spertus: I suspect not. It's challenging for the interventional community because we need a lot of interventionalists to provide 24/7 call for ST-elevation myocardial infarction. But I do think that this will decrease the frequency of angioplasty in stable coronary disease, primarily in the patients who are asymptomatic. We estimate that somewhere between 20% and 25% of patients are probably asymptomatic undergoing angioplasty and bypass surgery.
It's not clearunless there is a long-term follow-up that shows a much longer-term advantagethat there is a benefit from those procedures for the patients. Yes, that may lead to a decrease in the number of procedures, but about 75% or more of our procedures are done for acute coronary syndromes. I don't think there is anything in ISCHEMIA that will influence the bulk of revascularization procedures that are done. But in the stable cohort, I think it will. It should drop, frankly.
Jancin: Your investigative team got admirable rates of guideline-directed medical therapy adherence. Maybe more than in clinical practice.
Spertus: The rates were higher than in clinical practice but it was still disappointing. We still were not able to get 95%-plus of patients on all of the recommended therapiesthe intense statins, the antiplatelets, the beta-blockers. Getting them to stop smoking is very difficult; increasing physical activity and weight loss is very difficult. It's challenging to do optimal medical therapy.
Despite that, for the degree that we did accomplish it, we showed very favorable outcomes across the board and as good as an invasive revascularization strategy. A lot of work is needed to figure out new and better incentive programs for patients to adhere to recommended therapies, to stop smoking, to engage in activities. We've got to get better at using and sustaining the lifestyle and disease-modifying therapies that are now available. I think this provides maybe not a direct incentive to do that, but we certainly should be leaning toward that. It's the foundation of any therapy we offer our patients.
Jancin: That is the news from the American Heart Association on ISCHEMIA, a trial that caused enormous numbers of cardiologists in the main hall to gasp and suck in their breath.
Spertus: Thank you very much.
Follow Medscape on Facebook, Twitter, Instagram, and YouTube
Here is the original post:
John Spertus, MD, on the Practice-Changing ISCHEMIA Trial - Medscape
- Best 30 Cardiology in Secaucus, NJ with Reviews - YP.com [Last Updated On: April 12th, 2018] [Originally Added On: April 12th, 2018]
- Cardiology | Weill Cornell Medicine [Last Updated On: April 14th, 2018] [Originally Added On: April 14th, 2018]
- Cardiology Conferences 2018 | Cardiology Meetings 2018 ... [Last Updated On: April 26th, 2018] [Originally Added On: April 26th, 2018]
- Dr. Anil Goel, MD - Birmingham, MI - Cardiology & Clinical ... [Last Updated On: April 26th, 2018] [Originally Added On: April 26th, 2018]
- Clinical Physiology (Cardiology) MSc/PGDip | Middlesex ... [Last Updated On: May 15th, 2018] [Originally Added On: May 15th, 2018]
- Cardiology Conferences 2018 | Upcoming Cardiology ... [Last Updated On: May 16th, 2018] [Originally Added On: May 16th, 2018]
- Clinical Cardiology Section | Cleveland Clinic [Last Updated On: May 27th, 2018] [Originally Added On: May 27th, 2018]
- Journal of Clinical and Experimental Cardiology - Open ... [Last Updated On: June 6th, 2018] [Originally Added On: June 6th, 2018]
- Cardiology Summit 2018 | Cardiology Conferences | Heart ... [Last Updated On: June 23rd, 2018] [Originally Added On: June 23rd, 2018]
- Cardiology Clinical and Research Faculty Members ... [Last Updated On: June 26th, 2018] [Originally Added On: June 26th, 2018]
- Cardiology Conferences 2018 | Cardiology Congress 2018 ... [Last Updated On: June 26th, 2018] [Originally Added On: June 26th, 2018]
- About Us - New Jersey Cardiology Associates [Last Updated On: July 8th, 2018] [Originally Added On: July 8th, 2018]
- About Us - Ventura Clinical Trials [Last Updated On: August 16th, 2018] [Originally Added On: August 16th, 2018]
- Clinical Cardiology Made Ridiculously Simple: Michael A ... [Last Updated On: August 22nd, 2018] [Originally Added On: August 22nd, 2018]
- Clinical Cardiology - American Society of Preventive Cardiology [Last Updated On: October 2nd, 2018] [Originally Added On: October 2nd, 2018]
- Heart Surgery Hospital in india | Cardiology Treatment ... [Last Updated On: October 7th, 2018] [Originally Added On: October 7th, 2018]
- Clinical Cardiology - American Society of Preventive ... [Last Updated On: December 3rd, 2018] [Originally Added On: December 3rd, 2018]
- Guideline Clinical App - American College of Cardiology [Last Updated On: December 7th, 2018] [Originally Added On: December 7th, 2018]
- Journal of Clinical and Experimental Cardiology- Open ... [Last Updated On: December 12th, 2018] [Originally Added On: December 12th, 2018]
- Clinical Cardiology - Baptist Health [Last Updated On: December 30th, 2018] [Originally Added On: December 30th, 2018]
- Cardiology at Cancun: Topics in Clinical Cardiology [Last Updated On: February 5th, 2019] [Originally Added On: February 5th, 2019]
- Department of Cardiovascular Medicine, KU School of Medicine [Last Updated On: March 10th, 2019] [Originally Added On: March 10th, 2019]
- Towards Health Equality: Improving the Management of Cardiovascular Diseases in Women - International Atomic Energy Agency [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors - TCTMD [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF - TCTMD [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- Combining Nature and Technology, Luye Medical and Cleveland Clinic Join to Build a Future Hospital in Shanghai - Yahoo Finance [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- Will Renal Denervation for Hypertension Rise Again? - Medscape [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- Obstructive Sleep Apnea, Sleep Symptoms, and their Association with Cardiovascular Disease - DocWire News [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- CNE expands pulmonary, sleep services with Brigham & Women's physicians - Warwick Beacon [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- What I Am Most Looking Forward to at TCT 2019 - TCTMD [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- Serelaxin Not Linked to CV Mortality Reduction in Patients Hospitalized for Acute HF - The Cardiology Advisor [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- Sacubitril-Valsartan Not Linked to Lower Hospitalization Risk, CV Death in HFpEF - The Cardiology Advisor [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- FDA clears multiuse angiography systems from Siemens Healthineers - DOTmed HealthCare Business News [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- Balloon Pulmonary Angioplasty Effective for Chronic Thromboembolic PH - The Cardiology Advisor [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- RWJBarnabas Health, St. Luke's University Health launch clinical affiliation - FierceHealthcare [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- Bilirubin: A Novel Indicator of Infective Endocarditis Adverse Outcomes - The Cardiology Advisor [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS - TCTMD [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- Community-based Care Model Reduces CVD Risk - Managed Healthcare Executive [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- American College of Cardiology Steps Up: Equal Pay, Opportunities for All - TCTMD [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- FDA Approves Novo Nordisk's Oral Semaglutide, First GLP-1 in Pill Form - AJMC.com Managed Markets Network [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred - Medscape [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- Seeking Synergy: Bringing Cardiology into Your Enterprise Imaging Strategy - Health Imaging [Last Updated On: September 21st, 2019] [Originally Added On: September 21st, 2019]
- TCT 2019 Day Two: Transcatheter Valves, New and Old - TCTMD [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis - TCTMD [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival - Diagnostic and Interventional Cardiology [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3 - TCTMD [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy... [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Off Script: The New Gatekeepers of Procedural Education - TCTMD [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Study Shows Safety and Efficacy of Near Infrared Spectroscopy (NIRS) Imaging to Identify Patients and Plaques at an Increased Risk for MACE - BioSpace [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- The Heart of the Matter: Cardiovascular Fitness in Horses - United States Eventing Association [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Google parent Alphabet hires former FDA head Robert Califf to lead health strategy and policy - FierceHealthcare [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Inclisiran Benefits Patients With Familial Hypercholesterolemia and ASCVD - The Cardiology Advisor [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- AUGUSTUS: Best Benefit With Apixaban, P2Y12 Inhibitor Dual Therapy - Medscape [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis - Newswise [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Dapagliflozin Improves Heart Failure-Related Health Status in HFrEF - The Cardiology Advisor [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Remote Ischemic Conditioning Did Not Improve 12 Month Clinical Outcomes After STEMI - The Cardiology Advisor [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Insights from the European Society of Cardiology congress | Speaking of Medicine - PLoS Blogs [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates | - Diagnostic and Interventional Cardiology [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- AZ's Farxiga gets heart failure prevention okay from FDA - PMLiVE [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - BioSpace [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- The Epidemic Of The Metabolic Syndrome Among The Palestinians In The G | DMSO - Dove Medical Press [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosis - PRNewswire [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- Even With Same Diagnosis, Women Get Half the Heart Attack Treatments as Men - AJMC.com Managed Markets Network [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- Eva Dickerman, Andrew Weil - The New York Times [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- EHR vendor Veradigm and partners creating new shared data tools for researchers - Healthcare IT News [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- Evolocumab Well-tolerated as Add-on for Hypercholesterolemia Therapy - DocWire News [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- Deborah Heart and Lung Center announces affiliation with Cleveland Clinic Heart & Vascular Institute - Health Essentials from Cleveland Clinic [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- New Registry to Provide Insight into STEMI Occurrence, Treatment in North India | - Diagnostic and Interventional Cardiology [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- Finding Your Best Fit in Cardiology - TCTMD [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- Cardiology team expands to meet community need - The Union of Grass Valley [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- Deaths After Ablation of Atrial Fibrillation 'Concerning' in Real-World Analysis - TCTMD [Last Updated On: November 1st, 2019] [Originally Added On: November 1st, 2019]
- Cutler Family gifts $15 million to University Hospitals to transform mens health care - Newswise [Last Updated On: November 1st, 2019] [Originally Added On: November 1st, 2019]
- Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD - TCTMD [Last Updated On: November 1st, 2019] [Originally Added On: November 1st, 2019]
- Caregiving and the Soul of Medicine - Medscape [Last Updated On: November 1st, 2019] [Originally Added On: November 1st, 2019]
- STEMI Mortality Unaffected by Weekend, Weeknight, or Holiday Admission in France - TCTMD [Last Updated On: November 1st, 2019] [Originally Added On: November 1st, 2019]
- Cardiva Medical publishes positive results from the AMBULATE pivotal study Cardiology2.0 - Cardiology2.0 [Last Updated On: November 1st, 2019] [Originally Added On: November 1st, 2019]
- Gaps in Access to TAVR and SAVR: 'Something Needs to Be Done' - TCTMD [Last Updated On: November 1st, 2019] [Originally Added On: November 1st, 2019]
- Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical... [Last Updated On: November 1st, 2019] [Originally Added On: November 1st, 2019]
- Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential - 24/7 Wall St. [Last Updated On: November 7th, 2019] [Originally Added On: November 7th, 2019]
- Global Computed Tomography (CT) Scanners Devices and Equipment Market Report 2020: Major Players are GE Healthcare, Koninklijke Philips, Hitachi,... [Last Updated On: November 7th, 2019] [Originally Added On: November 7th, 2019]